You've probably seen the acronym in a lab report or a methods section. MLPA. Multiplex Ligation-dependent Probe Amplification. It sounds like something you'd need a PhD just to pronounce. But here's the thing — it's actually one of the most elegant, practical tools in molecular diagnostics, and understanding it doesn't require a genetics degree.
I first ran into MLPA back when I was troubleshooting a microarray that kept giving me noisy copy number data. Now, a colleague slid a kit across the bench and said, "Try this instead. It's cheaper, faster, and you don't need a scanner." She wasn't wrong.
What Is MLPA
At its core, MLPA is a method for detecting copy number changes — deletions, duplications, sometimes even methylation status — across dozens of targets in a single reaction. Think of it as a highly targeted, PCR-based alternative to microarray or FISH. But instead of hybridizing to a chip or a chromosome spread, it uses pairs of probes that only amplify when they're both bound next to each other on your target DNA That's the part that actually makes a difference..
The magic is in the ligation step. Each probe pair consists of two oligonucleotides: a left probe oligonucleotide (LPO) and a right probe oligonucleotide (RPO). Both have a target-specific sequence at one end and a universal primer sequence at the other. When they hybridize adjacently on the sample DNA, a ligase enzyme joins them into a single, amplifiable molecule. In practice, no adjacency? Plus, no ligation. No ligation? No amplification.
That's the whole trick. And it's brilliant.
The probe design matters more than you think
Each probe pair targets a specific genomic locus — usually an exon of a gene you care about. The probes are designed so that every amplified product has a unique length. Here's the thing — after PCR, you run the products on a capillary electrophoresis instrument (like a genetic analyzer) and read the peak heights. But each peak corresponds to one target. The height tells you the relative copy number That alone is useful..
You can multiplex 40–50 probes in one tube. Some commercial kits push that even higher.
It's not just for copy number
Here's what most people miss: MLPA can also detect methylation changes. Consider this: the trick is using methylation-sensitive restriction enzymes before the ligation step. If a CpG island is methylated, the enzyme can't cut. The probe binds. Here's the thing — you get a signal. That's why if it's unmethylated, the enzyme cuts, the probe can't bind, and the signal drops. That's why same workflow. Different biology.
Why It Matters / Why People Care
Copy number variation (CNV) is a major driver of genetic disease. But for years, the tools to detect it were either low-resolution (karyotyping), low-throughput (FISH), or expensive and data-heavy (microarray, NGS). MLPA filled a sweet spot: targeted, quantitative, affordable, and fast Simple, but easy to overlook..
Clinical labs love it for a reason. Practically speaking, it's not a screening tool in the broad sense. If you're screening for DMD deletions in Duchenne muscular dystrophy, or SMN1 copy number in spinal muscular atrophy, or MLH1/MSH2 deletions in Lynch syndrome — MLPA is often the first-line test. It's a "I know which gene, now tell me if there's a deletion" tool.
And it works on degraded DNA. FFPE samples? Here's the thing — no problem. Practically speaking, the probes are short — usually 100–150 bp total amplicon size. That's a huge advantage over long-range PCR or NGS library prep.
Real-world impact
A kid presents with developmental delay. Boom — duplication confirmed. You order a chromosomal microarray. In practice, microarray resolution isn't great at that locus. But the phenotype screams MECP2 duplication syndrome. You run MLPA. Plus, diagnosis made. Family counseled. It comes back clean. That happens more often than you'd think.
Or take hereditary cancer. Day to day, a patient meets criteria for Lynch syndrome. Guidelines now recommend both. Sequencing MLH1, MSH2, MSH6, PMS2, EPCAM is standard. MLPA catches them. But sequencing misses large deletions. Skipping MLPA means missing 10–15% of pathogenic variants in some genes Took long enough..
People argue about this. Here's where I land on it Easy to understand, harder to ignore..
How It Works (Step by Step)
Let's walk through the actual workflow. It's simpler than the name suggests Simple, but easy to overlook..
1. DNA denaturation and probe hybridization
You start with 50–200 ng of genomic DNA. Heat it to 98°C for a few minutes to denature. Cool to 60°C. That's why add the probe mix. The probes are in vast excess. They find their targets and hybridize overnight (usually 16 hours). This is the slow step. But it's hands-off Easy to understand, harder to ignore..
2. Ligation
Next morning, you add ligase (usually a thermostable one like Ligase-65) and incubate at 54°C for 15 minutes. Then you heat-inactivate the ligase at 98°C for 5 minutes. But only adjacently hybridized probes get joined. Done That's the whole idea..
3. PCR amplification
You take a tiny aliquot of the ligation reaction — like 2–5 µL — and add it to a PCR master mix with a single fluorescent primer pair (usually FAM-labeled forward, unlabeled reverse). 30–35 cycles. The universal primer sequences on every ligated probe mean one primer pair amplifies everything. That's it The details matter here..
4. Capillary electrophoresis
You dilute the PCR product, mix with formamide and a size standard, denature, and run on a 3130, 3500, or similar genetic analyzer. The instrument separates fragments by size and detects fluorescence. You get an electropherogram — peaks at known sizes.
5. Data analysis
This is where the magic turns into answers. In practice, ~0 = homozygous deletion. 5 = heterozygous deletion. Net is the standard for MRC-Holland kits) normalizes each sample against reference samples, corrects for slope, and calculates probe ratios. So 0 = normal copy number (two copies). Software (Coffalyser.~2.~1.Here's the thing — a ratio of ~1. ~0.5 = heterozygous duplication. 0 = homozygous duplication (rare, but happens) Less friction, more output..
The software also flags poor-quality runs: low signal, high background, failed reference probes. You learn to read the QC metrics like a dashboard.
Common Mistakes / What Most People Get Wrong
I've seen a lot of MLPA runs. Here's where things go sideways That's the whole idea..
Treating it like a yes/no assay
MLPA is quantitative. But it's not absolute quantitative. A probe ratio of 0.48 isn't automatically a deletion. Could be a SNP under the probe binding site. Could be a bad hybridization. Could be a mosaic sample. You need to look at the whole profile — multiple probes across the gene, flanking probes, reference probes. Context is everything.
Ignoring the reference probes
Every kit includes reference probes targeting stable genomic regions (usually on other chromosomes). They're your internal control. If your reference probes are noisy, your data is noisy. Don't just glance at the target peaks. Check the references first And it works..
Running without proper controls
You need at least three reference DNA samples per run. Ideally more. And they should be the same DNA extraction method as your test samples. FFPE vs. blood vs. saliva — they behave differently. Mix them and you'll chase ghosts Easy to understand, harder to ignore..
Assuming one kit fits all
MRC-Holland sells dozens of kits. P044 for DMD is not the same as P045 for *SMN1
6. Interpreting the Profile – Beyond the Numbers
The raw electropherogram is only the starting point. A disciplined interpretation workflow transforms a series of fluorescence peaks into biologically meaningful copy‑number calls.
-
Probe‑by‑probe scrutiny – Each target region is covered by at least two independent probes (one spanning the exon‑intron boundary, another within the coding sequence). Discordant signals between the two suggest a technical artefact rather than a true copy‑number change Simple as that..
-
Reference‑probe concordance – The ratio of a target probe to its internal reference should hover around 1.0 ± 0.1 in a well‑behaved run. Systematic drift across the entire electropherogram (e.g., all target ratios shifted down by 15 %) often points to incomplete denaturation, pipetting error, or a malfunctioning detector.
-
Mosaicism detection – In samples where only a subset of cells carries the alteration, the peak height for the abnormal allele may be reduced but not absent. Visual inspection of the peak shape, together with the presence of a secondary, smaller peak at the expected size, can reveal a mosaic pattern that would be missed if only a single cut‑off is applied Practical, not theoretical..
-
Allelic balance – For genes that are subject to imprinting or parental‑specific expression, the ratio may deviate from the simple “two‑copy = 1.0” expectation. In these contexts, the software’s built‑in statistical models (e.g., Bayesian clustering) become essential to differentiate true allelic imbalance from technical noise.
-
Copy‑number neutrality – Some genomic loci are inherently resistant to copy‑number variation (e.g., pericentromeric heterochromatin). Probes designed for such regions will rarely show deviation, and forcing a call can generate false positives. Selecting the appropriate kit for the target chromosome arm mitigates this risk.
7. Quality‑Control (QC) Checklist for Every Run
| QC Metric | Desired Range | Action if Out of Range |
|---|---|---|
| Reference‑probe mean fluorescence | 100 % ± 10 % of run‑specific baseline | Re‑run if > 15 % deviation; verify denaturation and injection volume |
| Slope of amplification plot | 0.05 (per kit) | Investigate PCR master mix preparation; replace reagents |
| Background level | < 5 % of target peak height | Clean capillary, replace capillary cartridge, check for carry‑over |
| Standard curve R² | > 0.95–1.98 | Re‑prepare size standard; verify capillary temperature control |
| Repeatability (duplicate samples) | ≤ 0. |
A pragmatic approach is to embed this checklist into the laboratory’s standard operating procedure (SOP). Automated alerts from the analysis software can flag failures, but a manual visual check of the electropherogram remains indispensable And it works..
8. Troubleshooting Common Pitfalls
| Problem | Likely Cause | Remedy |
|---|---|---|
| No amplification (flat baseline) | Incomplete ligation or degraded probe | Verify ligation time/temperature; ensure probes are stored at –20 °C and protected from freeze‑thaw cycles |
| Excessive background fluorescence | Residual formamide or inadequate denaturation | Increase denaturation temperature (95 °C) for an additional 30 s; confirm complete mixing of PCR product with loading dye |
| Smear or multiple peaks | Mis‑primed PCR or non‑specific products | Re‑design primers, add a hot‑start polymerase, or use a touchdown PCR protocol |
| Unexpected ratio shifts | SNP within probe binding site | Replace the probe with a non‑polymorphic version or redesign the probe to span a non‑variable region |
| High CV between replicates | Inconsistent sample handling or pipetting errors | Use automated liquid handlers, pre‑aliquot master mixes, and verify volume accuracy before each step |
9. Practical Applications
- Diagnostic genetics – Detecting deletions/duplications in neurofibromatosis type 1 (NF1), Charcot‑Marie‑Tooth disease PMP22, and other dosage‑sensitive disorders.
- Oncology – Identifying copy‑number alterations in tumor suppressor genes (TP53, PTEN) or oncogenes (MYC, ERBB2) that influence therapeutic decisions.
- Prenatal testing – Rapid screening of fetal DNA extracted from chorionic villi or amniotic fluid for common microdeletion syndromes (e.g., 22q11.2, Williams).
- Research – Mapping copy‑number dynamics during disease progression, monitoring clonal evolution in leukemia, or assessing the impact of CRISPR‑mediated deletions.
10. Limitations and Emerging Alternatives
While MLPA remains a cost‑effective, high‑throughput method for detecting relative copy‑number changes across many loci simultaneously, it does have inherent constraints:
- Resolution – The assay’s resolution is limited to the size of the PCR amplicon (typically 100–300 bp). Very small insertions or complex rearrangements may be missed.
- Quantitative accuracy – Because the method is semi‑quantitative, absolute copy‑number determination requires calibration with standards; it is not suitable for precise dosing in contexts such as dosage‑sensitive gene therapy.
- Allelic dropout – Variability in probe hybridization can obscure heterozygous states, especially in GC‑rich or highly repetitive regions.
To address these gaps, many laboratories now combine MLPA with complementary technologies:
- Next‑generation sequencing (NGS) panels for single‑base resolution and exhaustive coverage.
- Digital PCR for absolute quantification when a high‑precision metric is required.
- Array CGH or SNP arrays when genome‑wide copy‑number landscapes are needed.
Even so, MLPA’s simplicity, rapid turnaround (≈ 6 h from DNA to result), and ability to interrogate dozens of targets in a single reaction keep it firmly entrenched in both clinical and research settings.
Conclusion
MLPA is a powerful, relatively inexpensive tool that delivers quantitative copy‑number information across a broad genomic landscape in a single, streamlined workflow. Success hinges on meticulous adherence to the ligase‑PCR‑CE protocol, rigorous quality‑control of both reagents and instrumentation, and a nuanced interpretation that considers probe design, reference‑probe behavior, and sample‑specific context. By respecting these principles — and by avoiding the common pitfalls that can masquerade as biological findings — researchers and clinicians can extract reliable, actionable insights from MLPA data, thereby turning a simple electropherogram into a decisive diagnostic or investigative answer.
